Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Finranks

Kompaniya

  • Biz haqimizda

Biz bilan bog'lanish

  • [email protected]

Bizni kuzating

  • Instagram
  • Telegram
  • LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari
  • Bosh sahifa
  • Bozorlar
  • Skriner
  • Yangiliklar
  • Biz haqimizda
  1. Home
  3. APGE

(APGE)

NGM – Real vaqt narxi. Valyuta: USD

77.82

-0.60 (-0.77%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

79.99

+2.17 (2.79%)

Bozordan keyin: Mar 27, 2026, 7:36 PM EDT

  • Umumiy
  • Yangiliklar
  • Grafik
  • Hisobotlar
  • Dividendlar
  • Kutilma
  • Egalik
  • Profil

Videolar

No Data

There is no data to display

Press-relizlar

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
26.03.2026

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
25.03.2026

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on March 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
23.03.2026

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock are being offered by Apogee.

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
23.03.2026

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart